Почетна › Рак желуца › Јута
Kliničke studije za Рак желуца u državi Јута
14 studija za Рак желуца traži učesnike na lokacijama u državi Јута.
Gradovi u državi Јута
Zvanični tekst studije (na engleskom)
A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors
- Intermountain Health, Salt Lake City
Тражи се учесникФаза 1
Узраст 19 и старији · Оба пола · Ажурирано 5. 11. 2026. · NCT06586957A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors
- Utah Cancer Specialists, Salt Lake City
- University of Utah Health Huntsman Cancer Hospital, Salt Lake City
Тражи се учесникФаза 1/2
Узраст 18 и старији · Оба пола · Ажурирано 2. 11. 2026. · NCT03526835A Study of MGC026 in Participants With Advanced Solid Tumors
- START Mountain Region, West Valley City
Тражи се учесникФаза 1
Узраст 18 и старији · Оба пола · Ажурирано 28. 10. 2026. · NCT06242470A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors
- START Mountain Region, West Valley City
Тражи се учесникФаза 1/2
Узраст 18 и старији · Оба пола · Ажурирано 9. 10. 2026. · NCT07070232Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer
- University of Utah - Huntsman Cancer Institute, Salt Lake City
Тражи се учесникФаза 1/2
Узраст 18 и старији · Оба пола · Ажурирано 18. 9. 2026. · NCT05267626A Phase 1/1b Study of IAM1363 in HER2 Cancers
- START Mountain Region, West Valley City
Тражи се учесникФаза 1
Узраст 18 и старији · Оба пола · Ажурирано 9. 9. 2026. · NCT06253871A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors
- START Mountain Region, Salt Lake City
- South Texas Accelerated Research Therapeutics Mountain Region, West Valley City
Тражи се учесникФаза 1
Узраст 18 и старији · Оба пола · Ажурирано 22. 7. 2026. · NCT06131840A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
- START Mountain Region, West Valley City
Тражи се учесникФаза 1
Узраст 18 и старији · Оба пола · Ажурирано 22. 7. 2026. · NCT05208762A Study of CHS-114 (Tagmokitug) in Combination With Toripalimab and/or Other Treatments in Participants With Advanced Solid Tumors
- Huntsman Cancer Institute, University of Utah, Salt Lake City
- START Mountain Region, LLC., West Valley City
Тражи се учесникФаза 1
Узраст 18 и старији · Оба пола · Ажурирано 15. 7. 2026. · NCT06657144Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan
- Start Mountain Region /ID# 276270, West Valley City
Тражи се учесникФаза 1
Узраст 18 и старији · Оба пола · Ажурирано 23. 6. 2026. · NCT05005403Dose Determining Study of EXS74539 (REC-4539) in Participants With Select Solid Tumors
- START Mountain Region, West Valley City
Тражи се учесникФаза 1
Узраст 18 и старији · Оба пола · Ажурирано 10. 6. 2026. · NCT07517198Comparative Effectiveness Trial of Two Supportive Cancer Care Delivery Models for Adults With Cancer
- George E. Wahlen Department of Veterans Affairs Medical Center, Salt Lake City
Тражи се учесник
Узраст 18 и старији · Оба пола · Ажурирано 30. 4. 2026. · NCT05297734A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies
- START Center for Cancer Care - Mountain Region, Salt Lake City
Тражи се учесникФаза 1/2
Узраст 18 и старији · Оба пола · Ажурирано 27. 3. 2026. · NCT06395519SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Salt Lake City
Тражи се учесникОпсервациона студија
Сви узрасти · Оба пола · Ажурирано 28. 10. 2025. · NCT03452774Sa sajta ClinicalTrials.gov, podaci preuzeti 15. 11. 2026.. Svaka studija ima svoje kriterijume za uključivanje; tim studije odlučuje ko može da učestvuje.